GeNeuro SA
GEM
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
Are investors too bearish on Australian equities?
A new report suggests the pessimism might be overdone.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.90 | 5.00 | 0.05% |
| CAC 40 | 8,127.22 | 73.66 | -0.90% |
| DAX 40 | 24,078.34 | 45.87 | -0.19% |
| Dow JONES (US) | 47,632.00 | 74.37 | -0.16% |
| FTSE 100 | 9,694.27 | 61.87 | -0.63% |
| HKSE | 26,282.69 | 63.45 | -0.24% |
| NASDAQ | 23,958.47 | 130.98 | 0.55% |
| Nikkei 225 | 51,325.61 | 17.96 | 0.04% |
| NZX 50 Index | 13,459.29 | 50.08 | 0.37% |
| S&P 500 | 6,890.59 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,885.50 | 5.50 | 0.06% |
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |